SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPearson Regulatory News (PSON)

Share Price Information for Pearson (PSON)

Share Price is delayed by 15 minutes
Get Live Data
1,147.00    10.50 (0.92%)
Bid:
1,144.00
Ask:
1,145.00
Spread: 1.00 (0.087%)
Market Cap: £6.89b
PSON Live PriceLast checked at - London Stock Exchange

Intraday Pearson Share Chart

Form 8.3 - Pearson plc

29 Mar 2022 11:18

Form 8.3 - Pearson plc

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:Jupiter Fund Management Plc
(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. 
(c) Name of offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offereePearson plc
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: 
(e) Date dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure28th March 2022
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state “N/A”NO

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:25p Ordinary
 InterestsShort positions
 Number%Number%
(1) Relevant securities owned and/or controlled:9,152,7891.20  
(2) Cash-settled derivatives:893,6370.11  
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:    
TOTAL:10,046,4261.32  

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:None
Details, including nature of the rights concerned and relevant percentages:None

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant securityPurchase/saleNumber of securitiesPrice per unit
25p OrdPurchase1,6667.903533

(b) Cash-settled derivative transactions

Class of relevant securityProduct descriptione.g. CFDNature of dealinge.g. opening/closing a long/short position, increasing/reducing a long/short positionNumber of reference securitiesPrice per unit
     

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant securityProduct description e.g. call optionWriting, purchasing, selling, varying etc.Number of securities to which option relatesExercise price per unitTypee.g. American, European etc.Expiry dateOption money paid/ received per unit
NONE       

(ii) Exercise

Class of relevant securityProduct descriptione.g. call optionExercising/ exercised againstNumber of securitiesExercise price per unit
NONE    

(d) Other dealings (including subscribing for new securities)

Class of relevant securityNature of dealinge.g. subscription, conversionDetailsPrice per unit (if applicable)
    

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”
NONE

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:(i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:If there are no such agreements, arrangements or understandings, state “none”
NONE

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?NO

Date of disclosure:29th March 2022
Contact name:Claire Rodway
Telephone number:0203 817 1441

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

Date   Source Headline
28th Jul 20239:31 amRNSCommittee Changes
27th Jul 20239:48 amRNSDirector Declaration
19th Jul 20234:13 pmRNSDirector/PDMR Shareholding
4th Jul 20239:10 amRNSDirector/PDMR Shareholding
3rd Jul 20233:38 pmRNSTotal Voting Rights
14th Jun 20235:17 pmRNSHolding(s) in Company
1st Jun 202312:32 pmRNSBlock listing Interim Review
1st Jun 202312:28 pmRNSTotal Voting Rights
26th May 20234:48 pmRNSHolding(s) in Company
19th May 20233:00 pmRNSDirector/PDMR Shareholding
17th May 20234:50 pmRNSDirector/PDMR Shareholding
16th May 20234:16 pmRNSDirector/PDMR Shareholding
10th May 20234:30 pmRNSDirector/PDMR Shareholding
10th May 202310:49 amRNSDirectorate Change
9th May 20234:15 pmRNSHolding(s) in Company
9th May 20239:00 amRNSPearson: Generative AI Strategy Update
4th May 20234:30 pmRNSDirector/PDMR Shareholding
4th May 20234:30 pmRNSDirector/PDMR Shareholding
4th May 20234:30 pmRNSDirector/PDMR Shareholding
3rd May 20234:13 pmRNSHolding(s) in Company
2nd May 20233:57 pmRNSTotal Voting Rights
28th Apr 20231:11 pmRNSResult of AGM
28th Apr 20237:00 amRNSPearson 2023 Q1 Trading Update
20th Apr 20234:19 pmRNSHolding(s) in Company
11th Apr 20239:17 amRNSHolding(s) in Company
4th Apr 20234:30 pmRNSDirector/PDMR Shareholding
4th Apr 20234:00 pmRNSHolding(s) in Company
4th Apr 20237:00 amRNSDirector/PDMR Shareholding
3rd Apr 20233:00 pmRNSTotal Voting Rights
31st Mar 20233:44 pmRNSForm 20-F for the year ended 31 December 2022
31st Mar 20232:29 pmRNSHolding(s) in Company
28th Mar 202311:17 amRNSDirector Declaration
27th Mar 20234:05 pmRNSHolding(s) in Company
24th Mar 202312:30 pmRNSNotice of AGM
23rd Mar 20237:00 amRNSPearson Completes Acquisition of PDRI
21st Mar 20237:00 amRNSPearson to sell POLS
16th Mar 20233:09 pmRNSAnnual Financial Report
16th Mar 202311:28 amRNSDirector Declaration
7th Mar 20234:36 pmRNSDirector/PDMR Shareholding
3rd Mar 20237:00 amRNSPearson 2022 Preliminary Results
2nd Mar 20233:37 pmRNSCommittee Change
1st Mar 202310:10 amRNSTotal Voting Rights
8th Feb 20232:37 pmRNSHolding(s) in Company
3rd Feb 20234:23 pmRNSDirector/PDMR Shareholding
1st Feb 202311:10 amRNSTotal Voting Rights
18th Jan 20237:00 amRNSPearson 2022 Trading Update
4th Jan 20233:04 pmRNSDirector/PDMR Shareholding
3rd Jan 20239:25 amRNSTotal Voting Rights
19th Dec 202212:02 pmRNSDirector/PDMR Shareholding
19th Dec 202212:00 pmRNSPearson to Acquire PDRI

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.